- Pfizer (PFE, Financial) to present over 60 abstracts at ASCO 2025, showcasing advancements in oncology.
- Key studies include the BREAKWATER trial for colorectal cancer and VERITAC-2 study for breast cancer.
- Focus on achieving eight breakthrough cancer medicines by 2030 with nine new pivotal Phase 3 trials in 2025.
Pfizer Inc. (PFE) is set to highlight their extensive oncology portfolio with more than 60 abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 to June 3 in Chicago. The presentations will cover various cancer types, including breast, genitourinary, hematologic, and thoracic cancers, as well as advancements in colorectal cancer treatments.
Significant presentations will include the Phase 3 BREAKWATER study on BRAFTOVI® (encorafenib) combined with cetuximab and mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer. This study will showcase detailed analyses of overall survival and progression-free survival, providing important insights following its FDA accelerated approval in late 2024.
In breast cancer, the Phase 3 VERITAC-2 study will present data on vepdegestrant, a PROTAC ER degrader, in ER+/HER2- advanced or metastatic breast cancer. This study aims to support the continued development of vepdegestrant in collaboration with Arvinas.
Pfizer will also showcase five-year survival data from the Phase 3 ARCHES study of XTANDI® (enzalutamide) in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. Additionally, the MagnetisMM-6 study will present initial results for ELREXFIO® (elranatamab) in combination with daratumumab and lenalidomide for patients with newly diagnosed multiple myeloma.
Furthermore, Pfizer continues to explore novel vedotin antibody-drug conjugates (ADCs) in combination with immune checkpoint inhibitors, with initial Phase 1 data being presented for new ADCs in thoracic cancers.
This year, Pfizer is advancing up to nine new pivotal Phase 3 trials, with a strategic goal of delivering eight breakthrough cancer medicines by 2030. The company's presentations at ASCO 2025 underline its commitment to enhancing cancer care through innovative therapies and collaborative efforts.
